Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.26 -1.1%	$25.02	$22.64 ▼ $53.96	$1.20B	0.78	481,667 shs	476,324 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CDTX Cidara Therapeutics	$22.69 -5.5%	$20.77	$10.14 ▼ $28.42	$284.69M	0.86	79,500 shs	186,714 shs
OCUL Ocular Therapeutix	$7.89 +13.7%	$7.35	$4.79 ▼ $11.78	$1.26B	1.51	1.41 million shs	3.15 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+4.33%	+1.83%	+5.54%	-18.20%	-40.98%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+78.41%
CDTX Cidara Therapeutics	-1.15%	-10.78%	+11.42%	+8.45%	+99.67%
OCUL Ocular Therapeutix	-4.93%	-8.68%	-9.99%	0.00%	+19.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.3302 of 5 stars	3.1	1.0	3.7	4.0	4.2	1.3
CALT Calliditas Therapeutics AB (publ)	0.0721 of 5 stars	1.0	0.0	0.0	0.0	0.0	0.6
CDTX Cidara Therapeutics	4.2909 of 5 stars	4.6	3.0	4.6	2.2	0.8	0.0
OCUL Ocular Therapeutix	3.6345 of 5 stars	3.4	1.0	4.1	2.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	28.00% Upside
CALT Calliditas Therapeutics AB (publ)	2.00	Hold	$39.00	-2.50% Downside
CDTX Cidara Therapeutics	3.22	Buy	$41.86	84.47% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	105.96% Upside

Current Analyst Ratings Breakdown

Latest CDTX, CALT, OCUL, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/23/2025	CDTX Cidara Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$33.00 ➝ $35.00
5/9/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$46.00 ➝ $47.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/29/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$46.00 ➝ $46.00
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$730.66M	1.64	$3.52 per share	7.17	$13.35 per share	1.89
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CDTX Cidara Therapeutics	$302K	942.69	N/A	N/A	($1.82) per share	-12.47
OCUL Ocular Therapeutix	$59.65M	21.07	N/A	N/A	$0.79 per share	9.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$137.54M	$2.76	8.42	7.68	2.19	21.80%	26.44%	11.89%	8/6/2025 (Estimated)
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	8/11/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	8/6/2025 (Estimated)

Latest CDTX, CALT, OCUL, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.82	3.43	2.61
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CDTX Cidara Therapeutics	N/A	3.54	3.54
OCUL Ocular Therapeutix	0.19	13.01	12.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
CALT Calliditas Therapeutics AB (publ)	2.83%
CDTX Cidara Therapeutics	35.82%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.10%
CALT Calliditas Therapeutics AB (publ)	2.20%
CDTX Cidara Therapeutics	7.64%
OCUL Ocular Therapeutix	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,620	47.50 million	35.05 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
OCUL Ocular Therapeutix	230	159.30 million	151.71 million	Optionable

CDTX, CALT, OCUL, and AMPH Headlines

Recent News About These Companies

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Polar Asset Management Partners Inc.

May 28 at 5:52 AM | marketbeat.com

Insider Selling: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sells 1,862 Shares of Stock

May 28 at 5:46 AM | insidertrades.com

BNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 26 at 3:21 AM | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 23, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Deutsche Bank AG

May 22, 2025 | marketbeat.com

Ocular Therapeutix at RBC Conference: Strategic Advancements in Wet AMD Trials

May 21, 2025 | uk.investing.com

Graham Capital Management L.P. Takes $321,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 20, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Second Line Capital LLC

May 19, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Point72 Asset Management L.P.

May 19, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp

May 19, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 18, 2025 | marketbeat.com

Balyasny Asset Management L.P. Acquires New Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 17, 2025 | marketbeat.com

Patient Square Capital LP Raises Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 16, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Boosted by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

May 15, 2025 | marketbeat.com

Richard L. Md Lindstrom Purchases 10,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

May 14, 2025 | marketbeat.com

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard L. Md Lindstrom Acquires 10,000 Shares

May 13, 2025 | insidertrades.com

HC Wainwright Expects Weaker Earnings for Ocular Therapeutix

May 10, 2025 | marketbeat.com

William Blair Cuts Earnings Estimates for Ocular Therapeutix

May 10, 2025 | marketbeat.com

What is HC Wainwright's Forecast for OCUL FY2026 Earnings?

May 9, 2025 | marketbeat.com

Deep Track Capital LP Grows Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, CALT, OCUL, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.26 -0.27 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$25.32 +0.06 (+0.26%)

As of 06:43 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 05/27/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Cidara Therapeutics NASDAQ:CDTX

$22.69 -1.31 (-5.46%)

Closing price 04:00 PM Eastern

Extended Trading

$21.96 -0.73 (-3.22%)

As of 06:07 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Ocular Therapeutix NASDAQ:OCUL

$7.89 +0.95 (+13.69%)

Closing price 04:00 PM Eastern

Extended Trading

$7.99 +0.10 (+1.32%)

As of 07:56 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time